Table 2 Significantly upregulated/downregulated pathways modulated by knockdown of WWP1 in PC3
KEGG entry number | Number of genes | Upregulated annotations | P -value | Genes |
|---|---|---|---|---|
4630 | 11 | Jak-STAT signalling pathway | 2.25E-04 | SOS1, PIK3CA, PIK3R2, CCND1, CLCF1, IL6R, IL6ST, SPRED2, EP300, SPRY4, IL24 |
4010 | 15 | MAPK signalling pathway | 2.27E-04 | MRAS, PTPRR, PPM1B, SOS1, PPM1A, RAPGEF2, MAPK9, PPP3R1, MKNK2, TRAF6, MECOM, CASP3, MAP4K3, TAOK2, PLA2G10 |
5200 | 17 | Pathways in cancer | 2.51E-04 | PPARD, SOS1, KITLG, COL4A6, E2F3, FOXO1, PIK3CA, PIK3R2, CCND1, CDKN1B, MAPK9, TRAF6, EP300, MECOM, CASP3, FZD4, WNT5A |
4012 | 8 | ErbB signalling pathway | 3.09E-04 | SOS1, PIK3CA, PIK3R2, CDKN1B, HBEGF, MAPK9, RPS6KB2, ERBB3 |
5215 | 8 | Prostate cancer | 3.34E-04 | SOS1, E2F3, FOXO1, PIK3CA, PIK3R2, CCND1, CDKN1B, EP300 |
5220 | 7 | Chronic myeloid leukaemia | 5.65E-04 | SOS1, E2F3, PIK3CA, PIK3R2, CCND1, CDKN1B, MECOM |
5223 | 6 | Non-small-cell lung cancer | 5.75E-04 | SOS1, E2F3, PIK3CA, PIK3R2, CCND1, FOXO3 |
4664 | 7 | Fc epsilon RI signalling pathway | 7.80E-04 | SOS1, PIK3CA, PIK3R2, SYK, MAPK9, PRKCE, PLA2G10 |
5221 | 6 | Acute myeloid leukaemia | 8.51E-04 | PPARD, SOS1, PIK3CA, PIK3R2, CCND1, RPS6KB2 |
4350 | 7 | TGF-beta signalling pathway | 1.13E-03 | INHBB, RBL2, NOG, ID1, EP300, RPS6KB2, ACVR2B |
4910 | 9 | Insulin signalling pathway | 1.26E-03 | SOS1, FOXO1, PIK3CA, PIK3R2, PTPN1, INSR, MAPK9, MKNK2, RPS6KB2 |
5222 | 7 | Small-cell lung cancer | 1.31E-03 | COL4A6, E2F3, PIK3CA, PIK3R2, CCND1, CDKN1B, TRAF6 |
4930 | 5 | Type II diabetes mellitus | 1.99E-03 | PIK3CA, PIK3R2, INSR, MAPK9, PRKCE |
4110 | 8 | Cell cycle | 2.96E-03 | FZR1, E2F3, CCND1, RBL2, CDKN1B, ORC4, EP300, CDKN1C |
4722 | 8 | Neurotrophin signalling pathway | 3.11E-03 | SOS1, PIK3CA, PIK3R2, FRS2, MAPK9, TRAF6, FOXO3, PSEN1 |
4978 | 5 | Mineral absorption | 3.15E-03 | MT2A, SLC8A1, MT1M, MT1E, SLC40A1 |
5213 | 5 | Endometrial cancer | 3.43E-03 | SOS1, PIK3CA, PIK3R2, CCND1, FOXO3 |
4370 | 6 | VEGF signalling pathway | 3.52E-03 | PIK3CA, PIK3R2, KDR, PPP3R1, NOS3, PLA2G10 |
5010 | 9 | Alzheimer’s disease | 4.96E-03 | ADAM10, PPP3R1, ITPR2, CASP3, UQCR10, UQCRB, COX8C, CDK5R1, PSEN1 |
KEGG entry number | Number of genes | Downregulated annotations | P -value | Genes |
4110 | 10 | Cell cycle | 6.51E-10 | CDK6, PTTG2, CCNB2, CCNA2, TFDP1, BUB1B, CDC45, SMAD4, BUB1, CDK1 |
5146 | 6 | Amoebiasis | 1.25E-05 | IL1B, SERPINB3, CXCL1, SERPINB4, CSF2, FN1 |
4115 | 5 | p53 signalling pathway | 2.15E-05 | CDK6, CCNB2, THBS1, GTSE1, CDK1 |
5323 | 5 | Rheumatoid arthritis | 6.42E-05 | IL1B, CXCL6, CXCL1, LTB, CSF2 |
4512 | 4 | ECM-receptor interaction | 8.34E-04 | THBS1, ITGB8, COL6A3, FN1 |
4914 | 4 | Progesterone-mediated oocyte maturation | 9.10E-04 | CCNB2, CCNA2, BUB1, CDK1 |
4060 | 6 | Cytokine–cytokine receptor interaction | 1.94E-03 | IL1B, CXCL6, CXCL3, CXCL1, LTB, CSF2 |
4114 | 4 | Oocyte meiosis | 2.26E-03 | PTTG2, CCNB2, BUB1, CDK1 |
4510 | 5 | Focal adhesion | 3.12E-03 | MYL10, THBS1, ITGB8, COL6A3, FN1 |
4810 | 5 | Regulation of actin cytoskeleton | 4.01E-03 | DIAPH3, BDKRB2, MYL10, ITGB8, FN1 |
